INVA Key Statistics, Chart & Performance
The current stock price of INVA is 20.74 USD. In the past month the price increased by 0.78%. In the past year, price increased by 8.87%.
INVA Latest News, Press Relases and Analysis
INVA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 45.94 | 955.13B | ||
| JNJ | JOHNSON & JOHNSON | 19.45 | 486.51B | ||
| MRK | MERCK & CO. INC. | 11.32 | 247.51B | ||
| PFE | PFIZER INC | 8.13 | 148.00B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.95 | 106.16B | ||
| ZTS | ZOETIS INC | 18.71 | 52.29B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.67 | 22.93B | ||
| VTRS | VIATRIS INC | 4.69 | 12.59B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.81 | 10.88B | ||
| CORT | CORCEPT THERAPEUTICS INC | 97.85 | 9.06B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.52B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.23B |
Related stock screener links
About INVA
Company Profile
Innoviva, Inc. is engaged in the development, commercialization, and financial management of biopharmaceuticals. The company is headquartered in Burlingame, California and currently employs 127 full-time employees. The company went IPO on 2004-10-05. The firm's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. The firm's products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO (formerly known as sulbactam-durlobactam or SUL-DUR), is approved for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in Phase III clinical trial.
Company Info
INNOVIVA INC
1350 Old Bayshore Highway, Suite 400
Burlingame CALIFORNIA 94010 US
CEO: Pavel Raifeld
Employees: 127
Phone: 16502389600
INNOVIVA INC / INVA FAQ
Can you describe the business of INNOVIVA INC?
Innoviva, Inc. is engaged in the development, commercialization, and financial management of biopharmaceuticals. The company is headquartered in Burlingame, California and currently employs 127 full-time employees. The company went IPO on 2004-10-05. The firm's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. The firm's products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO (formerly known as sulbactam-durlobactam or SUL-DUR), is approved for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in Phase III clinical trial.
What is the current price of INVA stock?
The current stock price of INVA is 20.74 USD. The price decreased by -0.29% in the last trading session.
Does INNOVIVA INC pay dividends?
INVA does not pay a dividend.
What is the ChartMill rating of INNOVIVA INC stock?
INVA has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
On which exchange is INVA stock listed?
INVA stock is listed on the Nasdaq exchange.
What sector and industry does INNOVIVA INC belong to?
INNOVIVA INC (INVA) operates in the Health Care sector and the Pharmaceuticals industry.
Is INNOVIVA INC (INVA) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on INVA.
INVA Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to INVA. When comparing the yearly performance of all stocks, INVA turns out to be only a medium performer in the overall market: it outperformed 62% of all stocks.
INVA Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to INVA. Both the health and profitability get an excellent rating, making INVA a very profitable company, without any liquidiy or solvency issues.
INVA Financial Highlights
Over the last trailing twelve months INVA reported a non-GAAP Earnings per Share(EPS) of 1.37. The EPS increased by 98.55% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 32.78% | ||
| ROA | 8.91% | ||
| ROE | 12.61% | ||
| Debt/Equity | 0.25 |
INVA Forecast & Estimates
11 analysts have analysed INVA and the average price target is 37.54 USD. This implies a price increase of 80.98% is expected in the next year compared to the current price of 20.74.
For the next year, analysts expect an EPS growth of 526.32% and a revenue growth 7.36% for INVA